Pharming Group NV

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0010391025
EUR
1.47
-0.01 (-0.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with a -15.26% CAGR growth in Operating Profits over the last 5 years

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.32
2

With ROE of 0.57%, it has a Expensive valuation with a 4.41 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 950 Million ()

stock-summary
P/E

768.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

3.81%

stock-summary
Price to Book

4.22

Revenue and Profits:
Net Sales:
82 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.08%
0%
20.08%
6 Months
44.33%
0%
44.33%
1 Year
71.14%
0%
71.14%
2 Years
39.79%
0%
39.79%
3 Years
32.7%
0%
32.7%
4 Years
101.18%
0%
101.18%
5 Years
25.86%
0%
25.86%

Pharming Group NV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.67%
EBIT Growth (5y)
-15.26%
EBIT to Interest (avg)
-0.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.60
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.16%
ROE (avg)
7.42%
Valuation key factors
Factor
Value
P/E Ratio
768
Industry P/E
Price to Book Value
4.41
EV to EBIT
43.38
EV to EBITDA
28.76
EV to Capital Employed
4.66
EV to Sales
2.69
PEG Ratio
7.18
Dividend Yield
NA
ROCE (Latest)
10.74%
ROE (Latest)
0.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.31% vs -13.46% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 129.08% vs -502.86% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "82.20",
          "val2": "75.20",
          "chgp": "9.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.20",
          "val2": "2.80",
          "chgp": "335.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "4.80",
          "chgp": "-14.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "-7.40",
          "chgp": "74.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.10",
          "val2": "-14.10",
          "chgp": "129.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "119.10%",
          "val2": "4.70%",
          "chgp": "11.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.11% vs 16.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.22% vs -175.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "274.80",
          "val2": "226.90",
          "chgp": "21.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.80",
          "val2": "-10.20",
          "chgp": "166.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.20",
          "val2": "5.60",
          "chgp": "64.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-5.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.90",
          "val2": "-9.80",
          "chgp": "-11.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12.30%",
          "val2": "-89.80%",
          "chgp": "7.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
82.20
75.20
9.31%
Operating Profit (PBDIT) excl Other Income
12.20
2.80
335.71%
Interest
4.10
4.80
-14.58%
Exceptional Items
-1.90
-7.40
74.32%
Consolidate Net Profit
4.10
-14.10
129.08%
Operating Profit Margin (Excl OI)
119.10%
4.70%
11.44%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.31% vs -13.46% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 129.08% vs -502.86% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
274.80
226.90
21.11%
Operating Profit (PBDIT) excl Other Income
6.80
-10.20
166.67%
Interest
9.20
5.60
64.29%
Exceptional Items
-0.00
-5.40
100.00%
Consolidate Net Profit
-10.90
-9.80
-11.22%
Operating Profit Margin (Excl OI)
-12.30%
-89.80%
7.75%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 21.11% vs 16.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.22% vs -175.38% in Dec 2023

stock-summaryCompany CV
About Pharming Group NV stock-summary
stock-summary
Pharming Group NV
Pharmaceuticals & Biotechnology
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Coordinates stock-summary
Company Details
Darwinweg 24 , LEIDEN None : 2333 CR
stock-summary
Tel: 31 71 5247400
stock-summary
Registrar Details